New drug duo tested in fight against tough prostate cancer
NCT ID NCT03674814
Summary
This early-stage study is testing the safety of combining two drugs, enzalutamide and relacorilant, for men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The main goal is to find a safe dose and see how the drugs interact in the body. Researchers will also look for early signs that the combination might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.